000287457 001__ 287457
000287457 005__ 20241031120341.0
000287457 0247_ $$2doi$$a10.3389/fncel.2023.1332179
000287457 0247_ $$2pmid$$apmid:38298376
000287457 0247_ $$2pmc$$apmc:PMC10827848
000287457 0247_ $$2altmetric$$aaltmetric:159790193
000287457 037__ $$aDKFZ-2024-00249
000287457 041__ $$aEnglish
000287457 082__ $$a610
000287457 1001_ $$aPizzarelli, Rocco$$b0
000287457 245__ $$aInsulin-like growth factor 2 (IGF-2) rescues social deficits in NLG3-/y mouse model of ASDs.
000287457 260__ $$aLausanne$$bFrontiers Research Foundation$$c2024
000287457 3367_ $$2DRIVER$$aarticle
000287457 3367_ $$2DataCite$$aOutput Types/Journal article
000287457 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1707299793_6045
000287457 3367_ $$2BibTeX$$aARTICLE
000287457 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000287457 3367_ $$00$$2EndNote$$aJournal Article
000287457 520__ $$aAutism spectrum disorders (ASDs) comprise developmental disabilities characterized by impairments of social interaction and repetitive behavior, often associated with cognitive deficits. There is no current treatment that can ameliorate most of the ASDs symptomatology; thus, identifying novel therapies is urgently needed. Here, we used the Neuroligin 3 knockout mouse (NLG3-/y), a model that recapitulates the social deficits reported in ASDs patients, to test the effects of systemic administration of IGF-2, a polypeptide that crosses the blood-brain barrier and acts as a cognitive enhancer. We show that systemic IGF-2 treatment reverses the typical defects in social interaction and social novelty discrimination reflective of ASDs-like phenotypes. This effect was not accompanied by any change in spontaneous glutamatergic synaptic transmission in CA2 hippocampal region, a mechanism found to be crucial for social novelty discrimination. However, in both NLG3+/y and NLG3-/y mice IGF-2 increased cell excitability. Although further investigation is needed to clarify the cellular and molecular mechanisms underpinning IGF-2 effect on social behavior, our findings highlight IGF-2 as a potential pharmacological tool for the treatment of social dysfunctions associated with ASDs.
000287457 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000287457 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000287457 650_7 $$2Other$$aASDs
000287457 650_7 $$2Other$$aIGF-2
000287457 650_7 $$2Other$$aNLG3 -/y mouse
000287457 650_7 $$2Other$$ahippocampus
000287457 650_7 $$2Other$$asocial behavior
000287457 7001_ $$aPimpinella, Domenico$$b1
000287457 7001_ $$aJacobs, Christian$$b2
000287457 7001_ $$aTartacca, Alice$$b3
000287457 7001_ $$aKullolli, Uarda$$b4
000287457 7001_ $$0P:(DE-HGF)0$$aMonyer, Hannah$$b5
000287457 7001_ $$aAlberini, Cristina M$$b6
000287457 7001_ $$aGriguoli, Marilena$$b7
000287457 773__ $$0PERI:(DE-600)2452963-1$$a10.3389/fncel.2023.1332179$$gVol. 17, p. 1332179$$p1332179$$tFrontiers in cellular neuroscience$$v17$$x1662-5102$$y2024
000287457 8564_ $$uhttps://inrepo02.dkfz.de/record/287457/files/fncel-17-1332179.pdf
000287457 8564_ $$uhttps://inrepo02.dkfz.de/record/287457/files/fncel-17-1332179.pdf?subformat=pdfa$$xpdfa
000287457 909CO $$ooai:inrepo02.dkfz.de:287457$$pVDB
000287457 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT CELL NEUROSCI : 2022$$d2023-10-25
000287457 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-25
000287457 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-25
000287457 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-25
000287457 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-13T10:30:24Z
000287457 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-13T10:30:24Z
000287457 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2021-05-13T10:30:24Z
000287457 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-05-13T10:30:24Z
000287457 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-25
000287457 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-25
000287457 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-25
000287457 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-25
000287457 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-25
000287457 915__ $$0StatID:(DE-HGF)1040$$2StatID$$aDBCoverage$$bZoological Record$$d2023-10-25
000287457 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-25
000287457 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bFRONT CELL NEUROSCI : 2022$$d2023-10-25
000287457 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-10-25
000287457 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-10-25
000287457 9141_ $$y2024
000287457 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000287457 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000287457 9201_ $$0I:(DE-He78)A230-20160331$$kA230$$lA230 Klinische Neurobiologie$$x0
000287457 980__ $$ajournal
000287457 980__ $$aVDB
000287457 980__ $$aI:(DE-He78)A230-20160331
000287457 980__ $$aUNRESTRICTED